Trial Profile
A retrospective study of nivolumab patients with melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- 22 Jul 2018 New trial record